Business Context and Reporting Period
Company: Canton Strategic Holdings, Inc. (formerly Tharimmune, Inc.; Ticker: CNTN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: The Company executed a fundamental strategic pivot in November 2025, transitioning from a clinical-stage biotechnology firm to a digital asset treasury company. The new strategy focuses on acquiring, holding, and managing Canton Coin ("CC") to support the Canton Network, while maintaining legacy biotechnology operations through its subsidiary, Gravitas Life Sciences, Inc.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(35.9) million | $(12.2) million |
| Total Assets | $519.1 million | $3.7 million |
| Digital Assets (CC) | $501.8 million | $0 |
| Cash and Equivalents | $17.0 million | $3.6 million |
| Accumulated Deficit | $(72.8) million | $(36.9) million |
| Operating Cash Flow | $(16.1) million | $(10.9) million |
| Financing Cash Flow | $107.2 million | $3.5 million |
Note: The Company reported an unrealized loss of $22.0 million on digital asset holdings in 2025 due to fair value remeasurement.
Material Changes vs. Prior Period
- Strategic Pivot: Shifted primary focus from biotechnology R&D to a CC-centric digital asset treasury strategy in November 2025.
- Capital Raise: Raised approximately $537 million in net proceeds in November 2025 via a combined cash and cryptocurrency private placement (PIPE), significantly improving liquidity and removing the "going concern" uncertainty present in 2024.
- Asset Composition: Digital assets now comprise approximately 96.7% of total assets ($501.8 million), compared to zero in the prior year.
- Management Changes: Sireesh Appajosyula resigned as CEO in November 2025; Mark Wendland was appointed CEO and Chairman. Jacob Asbury was appointed CFO in December 2025.
- Operating Expenses: General and Administrative (G&A) expenses increased 182% to $17.0 million, driven by personnel costs, investor relations, and stock-based compensation. Research and Development (R&D) expenses decreased 52% to $3.1 million as clinical activities were deprioritized.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Treasury Strategy: The Company intends to operate as a Super Validator on the Canton Network, earn protocol rewards, and deploy capital into CC acquisitions and ecosystem investments.
- Liquidity: Management believes current resources are sufficient to fund operations through at least March 2027.
- Biotech Pipeline: Legacy programs (GV104, GV023) remain in development but are no longer the primary strategic focus. GV104 NDA submission is anticipated in H1 2027.
Key Risks and Contingencies:
- Asset Volatility: Financial results are highly correlated with the price of Canton Coin, which is subject to extreme volatility and regulatory uncertainty.
- Regulatory Classification: If CC is reclassified as a security, the Company could be deemed an "investment company" under the 1940 Act, imposing significant regulatory burdens.
- Cybersecurity and Custody: Risks include loss of private keys, hacking, and counterparty risk with custodians.
- Tax Liability: Unrealized gains on CC holdings may trigger the Corporate Alternative Minimum Tax (CAMT) under the Inflation Reduction Act.
Investor Verification Checklist
- CC Valuation: Verify the fair value methodology and the specific exchange/market data source used to value the $501.8 million CC holding.
- Custody Arrangements: Confirm the identity of institutional custodians and the extent of insurance coverage for the digital assets.
- Related Party Transactions: Review the $77.6 million purchase of CC from an affiliate liquidity provider controlled by a >5% shareholder.
- Warrant Dilution: Assess the impact of ~169 million pre-funded warrants and ~10.3 million strategic advisor warrants on future share count and dilution.
- Going Concern Status: Confirm that the removal of the going concern qualification is sustained given the high burn rate and reliance on asset appreciation.